-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
On November 1, AstraZeneca announced that it had agreed to transfer the global rights of Eklira (Aclidinium Bromide) and Duaklir (Aclidinium Bromide/Formoterol) to Covis Pharma for US$270 million
.
Both drugs are used to treat patients with chronic obstructive pulmonary disease (COPD)
.
According to the agreement, Covis Pharma will pay AstraZeneca US$270 million after the transaction is completed, and at the same time bear the subsequent development costs of the drug
.
The transaction is expected to be completed in the fourth quarter of 2021
.
Eklira is a long-acting muscarinic antagonist (LAMA), which was approved for marketing in the European Union and the United States in 2012
.
Duaklir is a combination therapy that includes LAMA and a long-acting β2-agonist (LABA).
It was the first to be marketed in the European Union in 2014 and was approved for marketing in the United States in 2019
Both drugs are inhaled respiratory system drugs for maintenance treatment of COPD patients, originally developed by Almirall
.
In July 2014, AstraZeneca acquired Almirall's respiratory system product line for US$875 million, including two drugs in this transaction
.
Previously, in November 2018, Covis Pharma acquired AstraZeneca’s 3 respiratory drugs Alvesco (ciclesonide inhalation aerosol), Omniris (ciclesonide nasal spray) and Zetonna (ciclesonide nasal spray) Aerosol) rights, the transaction amount exceeds 350 million US dollars
